Try
Telix Pharmaceuticals Ltd
TLXUnited States
5 filed reports · 367 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
5 reports · Dec 2024 to Sep 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 20-FSEC EDGAR | 2 | 2,080 | Dec 2024 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 2 | 321 | Jun 2026 to Sep 2026 |
| Annual · 20-F/ASEC EDGAR | 1 | 1 | Dec 2025 |
Financial data
367 concepts · 2,402 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial339 concepts · 1,975 facts · Dec 2022 to Jun 2026
- ANMI35 · Dec 2022 to Jun 2026
- Employee benefit obligations22 · Dec 2023 to Jun 2026
- Cash and cash equivalents16 · Dec 2022 to Jun 2026
- Equity16 · Dec 2022 to Jun 2026
- 1-6 months13 · Dec 2024 to Jun 2026
- Deferred tax assets13 · Dec 2023 to Jun 2026
- Lease liabilities13 · Dec 2022 to Jun 2026
- Property plant and equipment13 · Dec 2022 to Jun 2026
- Rightofuse assets13 · Dec 2022 to Jun 2026
- Intangible Assets12 · Dec 2022 to Dec 2025
- Liabilities arising from financing activities12 · Dec 2022 to Dec 2025
- Provisions12 · Dec 2022 to Dec 2025
- Tax Losses12 · Dec 2022 to Dec 2025
- Assets (IFRS)11 · Dec 2023 to Jun 2026
- Current assets11 · Dec 2023 to Jun 2026
- Current contract liabilities (IFRS)11 · Dec 2023 to Jun 2026
- Current lease liabilities (IFRS)11 · Dec 2023 to Jun 2026
- Current liabilities11 · Dec 2023 to Jun 2026
- Current provisions (IFRS)11 · Dec 2023 to Jun 2026
- Current tax assets current11 · Dec 2023 to Jun 2026
- Current tax liabilities current11 · Dec 2023 to Jun 2026
- Deferred tax liabilities (IFRS)11 · Dec 2023 to Jun 2026
- Intangible assets and goodwill (IFRS)11 · Dec 2023 to Jun 2026
- Inventories11 · Dec 2023 to Jun 2026
Segment22 concepts · 350 facts · Dec 2022 to Jun 2026
- Research and development expense (IFRS)66 · Dec 2022 to Dec 2025
- Intangible Assets (excluding Goodwill)29 · Dec 2024 to Dec 2025
- Revenue24 · Dec 2022 to Jun 2026
- Cost of sales18 · Dec 2022 to Dec 2025
- Depreciation and amortisation expense18 · Dec 2022 to Dec 2025
- General and administrative expense (IFRS)18 · Dec 2022 to Dec 2025
- Gross profit (IFRS)18 · Dec 2022 to Dec 2025
- Manufacturing and distribution costs18 · Dec 2022 to Dec 2025
- Other gains losses18 · Dec 2022 to Dec 2025
- Profit loss from operating activities18 · Dec 2022 to Dec 2025
- Total Assets15 · Dec 2023 to Jun 2026
- Total Liabilities15 · Dec 2023 to Jun 2026
- Additions to noncurrent assets (IFRS)12 · Dec 2023 to Dec 2025
- Operating segments9 · Dec 2023 to Dec 2025
- Operating Segments9 · Dec 2022 to Dec 2024
- Sales and marketing expense9 · Dec 2023 to Dec 2025
- Cost of Revenue6 · Jun 2025 to Jun 2026
- Depreciation & Amortization6 · Jun 2025 to Jun 2026
- General and Administrative Expense6 · Jun 2025 to Jun 2026
- Gross Profit6 · Jun 2025 to Jun 2026
- Operating Income6 · Jun 2025 to Jun 2026
- R&D Expense6 · Jun 2025 to Jun 2026
Product4 concepts · 45 facts · Dec 2022 to Dec 2025
- Intangible Assets (excluding Goodwill)22 · Dec 2023 to Dec 2024
- Manufacturing and distribution costs15 · Dec 2023 to Dec 2025
- Research and development expense (IFRS)6 · Dec 2022 to Dec 2025
- Radiopharmaceutical Production Facility2 · Dec 2024 to Dec 2025
Geography1 concepts · 31 facts · Dec 2022 to Jun 2026
- Revenue31 · Dec 2022 to Jun 2026
Guidance1 concepts · 1 facts · Sep 2026
- Revenue Guidance1 · Sep 2026
Segments
426 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments6 members · 350 facts
- Therapeutics91 · Dec 2022 to Dec 2025
- Precision Medicine85 · Dec 2022 to Dec 2025
- Manufacturing Solutions73 · Dec 2022 to Dec 2025
- Therapeutics36 · Dec 2023 to Jun 2026
- Precision medicine35 · Dec 2023 to Jun 2026
- Manufacturing solutions30 · Dec 2023 to Jun 2026
Geographical areas9 members · 31 facts
- Foreign Countries6 · Dec 2022 to Dec 2025
- US6 · Dec 2022 to Dec 2025
- AU3 · Dec 2022 to Dec 2024
- BE3 · Dec 2022 to Dec 2024
- CA3 · Dec 2022 to Dec 2024
- CN3 · Dec 2023 to Dec 2025
- GB3 · Dec 2022 to Dec 2024
- Us2 · Jun 2025 to Jun 2026
- Foreign countries2 · Jun 2025 to Jun 2026
Products and services15 members · 30 facts
- Product Development6 · Dec 2022 to Dec 2025
- Copyrights patents and other industrial property rights service and operating rights2 · Dec 2023 to Dec 2024
- Radiopharmaceutical Production Facility2 · Dec 2024 to Dec 2025
- Brussels south and optimal tracers2 · Dec 2023 to Dec 2024
- Dedicaid qdose2 · Dec 2023 to Dec 2024
- Sensei2 · Dec 2023 to Dec 2024
- Tlx1012 · Dec 2023 to Dec 2024
- Tlx3002 · Dec 2023 to Dec 2024
- Tlx591 cdx illuccix2 · Dec 2023 to Dec 2024
- Tlx5912 · Dec 2023 to Dec 2024
- Tlx662 · Dec 2023 to Dec 2024
- Artms1 · Dec 2024
- Iso therapeutics1 · Dec 2024
- Qsam153 sm dotmp1 · Dec 2024
- Tlx66-cdx1 · Dec 2024
Product or service5 members · 15 facts
- Global Manufacturing Costs3 · Dec 2023 to Dec 2025
- Quality Costs3 · Dec 2023 to Dec 2025
- Radiopharmacy Operations3 · Dec 2023 to Dec 2025
- Supply Chain Costs3 · Dec 2023 to Dec 2025
- Technical Services3 · Dec 2023 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.